Global Prevalence of Prediabetes.


Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
01 07 2023
Historique:
received: 07 12 2022
accepted: 10 04 2023
pmc-release: 01 07 2024
medline: 22 6 2023
pubmed: 17 5 2023
entrez: 17 5 2023
Statut: ppublish

Résumé

To estimate the global, regional, and national prevalence of prediabetes, defined by impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). We reviewed 7,014 publications for high-quality estimates of IGT (2-h glucose, 7.8-11.0 mmol/L [140-199 mg/dL]) and IFG (fasting glucose, 6.1-6.9 mmol/L [110-125 mg/dL]) prevalence for each country. We used logistic regression to generate prevalence estimates for IGT and IFG among adults aged 20-79 years in 2021 and projections for 2045. For countries without in-country data, we extrapolated estimates from countries with available data with similar geography, income, ethnicity, and language. Estimates were standardized to the age distribution for each country from the United Nations. Approximately two-thirds of countries did not have high-quality IGT or IFG data. There were 50 high-quality studies for IGT from 43 countries and 43 high-quality studies for IFG from 40 countries. Eleven countries had data for both IGT and IFG. The global prevalence of IGT in 2021 was 9.1% (464 million) and is projected to increase to 10.0% (638 million) in 2045. The global prevalence of IFG in 2021 was 5.8% (298 million) and is projected to increase to 6.5% (414 million) in 2045. The 2021 prevalence of IGT and IFG was highest in high-income countries. In 2045, the largest relative growth in cases of IGT and IFG would be in low-income countries. The global burden of prediabetes is substantial and growing. Enhancing prediabetes surveillance is necessary to effectively implement diabetes prevention policies and interventions.

Identifiants

pubmed: 37196350
pii: 148937
doi: 10.2337/dc22-2376
pmc: PMC10442190
doi:

Substances chimiques

Blood Glucose 0

Banques de données

figshare
['10.2337/figshare.22639039']

Types de publication

Review Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1388-1394

Subventions

Organisme : NHLBI NIH HHS
ID : K24 HL152440
Pays : United States

Informations de copyright

© 2023 by the American Diabetes Association.

Références

Diabetes Care. 2009 Jul;32(7):1327-34
pubmed: 19502545
Nat Rev Endocrinol. 2013 Jan;9(1):13-27
pubmed: 23165161
BMJ. 2016 Nov 23;355:i5953
pubmed: 27881363
Diabetologia. 2006 Feb;49(2):289-97
pubmed: 16391903
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Cochrane Database Syst Rev. 2018 Oct 29;10:CD012661
pubmed: 30371961
Diabetes Res Clin Pract. 2011 Dec;94(3):322-32
pubmed: 22100977
Global Health. 2019 Feb 1;15(1):10
pubmed: 30709362
Annu Rev Public Health. 2021 Apr 1;42:59-77
pubmed: 33355476
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
Diabetes Care. 2007 Mar;30(3):753-9
pubmed: 17327355
BMJ Open. 2016 Dec 21;6(12):e013806
pubmed: 28003299
Diabetes Care. 2018 Jul;41(7):1526-1534
pubmed: 29934481
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175
Lancet Diabetes Endocrinol. 2017 Jan;5(1):34-42
pubmed: 27863979
Diabetes Care. 2006 May;29(5):1130-9
pubmed: 16644654
Diabetes Care. 2017 Oct;40(10):1331-1341
pubmed: 28500215
Diabetes Care. 2020 Jan;43(1):152-160
pubmed: 31719054
N Engl J Med. 2001 May 3;344(18):1343-50
pubmed: 11333990
Diabetes. 2009 Apr;58(4):773-95
pubmed: 19336687
Diabetes Care. 1997 Apr;20(4):537-44
pubmed: 9096977
Diabetes Res Clin Pract. 2022 Jan;183:109119
pubmed: 34879977

Auteurs

Mary R Rooney (MR)

1Department of Epidemiology and Welch Center for Prevention, Epidemiology, & Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Michael Fang (M)

1Department of Epidemiology and Welch Center for Prevention, Epidemiology, & Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Katherine Ogurtsova (K)

2Environmental Epidemiology Group, Institute of Occupational, Social and Environmental Medicine, Centre for Health and Society, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Bige Ozkan (B)

1Department of Epidemiology and Welch Center for Prevention, Epidemiology, & Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Justin B Echouffo-Tcheugui (JB)

3Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, Baltimore, MD.

Edward J Boyko (EJ)

4Seattle Epidemiologic Research and Information Center, VA Puget Sound Health Care System, Seattle, WA.

Dianna J Magliano (DJ)

5Baker Heart and Diabetes Institute & School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Elizabeth Selvin (E)

1Department of Epidemiology and Welch Center for Prevention, Epidemiology, & Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH